PetVivo Holdings, Inc. Addresses Veterinary Industry's GEN Z Problem With Breakthrough AI License Agreement

Rhea-AI Summary

PetVivo Holdings (OTCQX: PETV) entered an exclusive 10-year white-label B2B licensing agreement with Digital Landia for Agentic Pet AI, a two-sided platform linking Gen Z pet parents to veterinary clinics. The deal includes 1 million restricted shares and covers 5 patent-pending innovations and 9 AI diagnostic agents. PetVivo cites a Q1 FY2026 revenue growth of 141% YoY and record fiscal 2025 revenue of $1.13 million. The companies plan a dual-platform launch in Q1 2026 targeting a $4.9 billion US veterinary AI market and 30,000+ clinics, claiming potential client acquisition costs of $1.50–$5.00.

Positive

• Exclusive 10-year B2B rights to Agentic Pet AI
• Record fiscal 2025 revenue of $1.13 million
• 141% YoY Q1 FY2026 revenue growth
• Addressable market $4.9 billion and 30,000+ clinics
• 1 million restricted shares strategic investment
• 5 patent-pending technology innovations

Negative

• Small absolute revenue: $1.13 million fiscal 2025
• 1 million restricted shares may dilute shareholders
• Launch timing dependent on dual-platform rollout in Q1 2026

Insights

Veterinary SaaS Commercial Strategist

Exclusive 10-year AI licensing deal and reported growth position PetVivo to commercialize a dual B2C/B2B platform starting Q1 2026.

PetVivo secures exclusive B2B veterinary market rights for 10 years and reports record fiscal 2025 revenue of $1.13 million with 141% year‑over‑year growth in Q1 FY2026. The agreement includes 1 million restricted shares and five patent‑pending innovations supporting nine diagnostic AI agents. The commercial model combines a freemium B2C app with a subscription/lead‑generation B2B platform, creating direct data flow from opted‑in pet parents to clinic systems and automated upload of longitudinal patient histories at booking.

The value drivers disclosed are clear: exclusive distribution rights, measurable acquisition‑cost reductions claimed ($1.50–$5.00 per outreach versus $50–$150+), and stated access to a demographic representing 57% of pet parents. Dependencies and risks are explicit in the content: successful simultaneous launch of the Agentic Pet app and B2B platform in Q1 2026, clinic onboarding at meaningful scale across the stated 1,000+ existing clinic relationships, and adoption of premium subscriptions at the disclosed $9.99/month price point. Monitor adoption metrics, conversion rates from freemium to premium, clinic integration progress, and early retention statistics within the first 6–12 months after the Q1 2026 launch to validate the claimed acquisition‑cost and efficiency improvements.

MINNEAPOLIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., an emerging biomedical device company focused on the commercialization of groundbreaking medical products for horses and companion animals, today announced it has entered into an exclusive 10-year white-label licensing agreement with Digital Landia Holding Corp for breakthrough Agentic Pet AI technology. The Agentic Pet AI technology addresses two critical challenges facing the veterinary industry: i) skyrocketing client acquisition costs, and ii) the difficulties in capturing the exploding Gen Z pet parent demographic.

The implementation of the Agentic Pet AI technology has the potential to deliver a 90% - 98% reduction in client acquisition costs, dropping from $50 - $150+ per client to just $1.50 - $5.00 per targeted outreach, while simultaneously providing veterinary practices with unprecedented access to this fastest-growing segment of Gen Z pet parents.

THE OPPORTUNITY: GEN Z PET BOOM MEETS MARKETING VOID

A seismic demographic shift is reshaping the pet care industry and veterinary practices around the world, which requires adaptation. Gen Z pet parenthood surged 43.5% in 2024 alone, with Gen Z and Millennials now representing 57% of all pet parents in America.

The generational differences are striking. While previous generations viewed pets as companions, 48% of Gen Z consider their pets actual children, fundamentally changing their approach to pet healthcare. Cat parenthood is exploding among this demographic, up 18% year over year.

The veterinary industry is beginning to take notice of this shift in customer demographic. Despite this seismic shift, many veterinary practices still allocate their modest marketing budgets toward traditional channels targeting older dog owners, creating a potential disconnect with the tech-savvy, data-driven, companion animal-loving generation that represents the future client of veterinary practitioners.

THE SOLUTION: TWO-SIDED PLATFORM REVOLUTION

The PetVivo – Digital Landia partnership solves both problems through an innovative two-sided platform connecting tech-savvy pet parents with forward-thinking veterinary practices.

On the consumer side, Digital Landia Holding Corp operates the Agentic Pet freemium app featuring 9 specialized AI diagnostic agents that track symptoms, behavior, nutrition, and wellness. Pet parents can use basic features free or upgrade to premium ($9.99/month) for advanced diagnostics, breed-specific monitoring, and comprehensive AI health reports.

When pet parents opt in to receive offers from nearby veterinarians, their complete dataset automatically flows to participating practices through PetVivo's B2B platform. When pet parents book appointments, all pet health data uploads directly to the veterinarian's system, eliminating intake forms and manual history taking entirely.

For veterinary practices, the benefits are transformative. Client acquisition costs are expected to plummet 90% - 98%. When pet parents book appointments, their complete AI-generated health data automatically uploads to the vet's B2B platform. The platform's 9 AI diagnostic agents assist with ALL patients, not just those connected through the app. Walk-ins benefit from real-time symptom analysis, behavioral pattern recognition, emergency triage assessment, and breed-specific health monitoring. Practices gain direct connection to the underserved Gen Z and Millennial market representing 57% of current pet parents.

REAL-WORLD IMPACT

Consider Sarah, 24, who tracks her rescue cat Luna's health on the Agentic Pet app for 8 weeks. When Luna develops symptoms, Sarah opts in. Dr. Martinez's practice receives an instant alert and when Sarah books her appointment, Luna's complete 8-week health history automatically uploads to Dr. Martinez's B2B platform, including AI preliminary diagnosis; a tool that may assist Dr. Martinez in making the final diagnosis of Luna’s medical condition.

The economics are compelling. Dr. Martinez's acquisition cost: $3.50 versus traditional $80 - $120. Time savings: 15+ minutes on history gathering. Client quality: highly engaged Gen Z pet parent who invested in premium health tracking and arrives informed and prepared.

Later that day, Dr. Martinez uses the platform's AI agents to assist in the diagnosis of a walk-in patient not using Agentic Pet, saving 10+ additional minutes. The platform delivers value for 100% of patients, not just new leads.

Six months later, Dr. Martinez's practice has acquired 47 Gen Z clients through the platform at a total cost of $164.50, compared to $3,760 - $5,640 through traditional marketing. The practice sees a 30% increase in preventive care visits as AI assists in identifying issues early, with overall consultation efficiency improving 20% across the entire patient base.

EXCLUSIVE 10-YEAR AGREEMENT

The PetVivo – Digital Landia partnership grants PetVivo the exclusive B2B veterinary market rights for 10 years, backed by strategic investment including 1 million restricted shares. The underlying technology features 5 patent-pending innovations with 9 specialized diagnostic agents accessible to veterinarians for all patients. The dual-platform launch in Q1 2026 introduces both Digital Landia Holding Corp's Agentic Pet B2C app and PetVivo's B2B platform simultaneously, creating immediate network effects.

MARKET OPPORTUNITY & INVESTOR VALUE

PetVivo enters a $4.9 billion US veterinary AI market with 30,000+ addressable clinics. The company's existing relationships with 1,000+ veterinary clinics provide immediate distribution capability, while recent momentum shows 141% year-over-year growth in Q1 FY2026 on record fiscal 2025 revenue of $1.13 million.

For shareholders, the agreement delivers exclusive positioning with a 10-year competitive advantage, multiple revenue streams including B2B subscriptions and lead generation fees, and powerful platform network effects. The AI diagnostic assistance facilitates rapid adoption as the platform becomes valuable infrastructure for veterinary practices, while demographic tailwinds provide sustained growth as Gen Z pet parenthood continues its 43.5% annual surge.

"We're addressing the veterinary industry's Gen Z opportunities while transforming how all veterinary care is delivered," stated John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "A practice might acquire 50 new Gen Z clients through the platform at $3.50 each, but they'll use the AI agents across their entire patient base of thousands. Vets will interact with the most engaged clients they've ever experienced at a fraction of traditional costs, with AI-powered diagnostic assistance that makes every consultation more efficient."

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG with OsteoCushion technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.

About Digital Landia Holding Corp

Digital Landia Holding Corp is an emerging technology company that created the proprietary Agentic Pet AI framework. The Agentic Pet AI framework features nine specialized diagnostic agents and 5 patent-pending innovations. The company operates a freemium B2C business model with premium subscriptions at $9.99/month providing advanced AI diagnostics and seamless dataset sharing with veterinary professionals.

Agentic pet is a next generation AI framework that autonomously creates, certifies, and evolves specialized “super agents” to deliver real time, data driven insights across the full spectrum of pet wellbeing. Owned by Digital Landia, Agentic pet combines multi modal data (audio, video, lab results, IoT sensors) with swarm intelligence to redefine personalized pet care.

CONTACT:

John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com 
(952) 405-6216

Media Relations:

team@digitallandia.com | www.digitallandia.com

Forward-Looking Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Attachment

• PetVivo Holdings, Inc.

FAQ

What did PetVivo (PETV) announce on October 21, 2025?

PetVivo announced a 10-year exclusive B2B license with Digital Landia for Agentic Pet AI and a strategic investment of 1 million restricted shares.

When will PetVivo and Digital Landia launch the Agentic Pet platforms?

The companies plan a simultaneous dual-platform launch in Q1 2026.

How could Agentic Pet AI affect veterinary client acquisition costs for PETV partners?

PetVivo projects client acquisition costs could drop to $1.50–$5.00 per targeted outreach from prior ranges of $50–$150+.

What financial traction did PetVivo report ahead of the AI agreement?

PetVivo reported record fiscal 2025 revenue of $1.13 million and 141% YoY growth in Q1 FY2026.

How large is the market opportunity cited by PetVivo for Agentic Pet AI?

PetVivo cites a $4.9 billion US veterinary AI market with over 30,000 addressable clinics.

What patented or proprietary assets are included with the PETV agreement?

The agreement includes 5 patent-pending innovations and 9 AI diagnostic agents accessible to veterinarians.